Diagnostic Assay:Article Title: Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion
Article Snippet: .. 2 , 0 , Tissue based , Knight Cancer Institute/Knight Diagnostic Laboratories , Sequenom MassARRAY system-multiplex PCR amplification of gene exons of interest; primer extension reaction using TYPLEX chemistry; readout of primer extension products by mass spectrometry. Multiplex panel of 496 assays that can detect up to 643 different mutations. , 10% , Not provided Only approximately 20% of potential mutations are covered in the TP53 gene.. .. 7 , 7 , Tissue based , MDACC 50-Gene Somatic Mutation Analysis Panel , PCR-based sequencing using a NGS-platform on genomic DNA to screen for mutations in the coding sequence of 50 genes , SNV 5%-10% , Hotspot technology PTEN 1 (1-25), 3 (55-70), 5 (99-135), 6 (165-184), 7 (212-215), 7 (231-267), 8 (282-300), 8 (312-342) TP53 2(1-20), 4 (68-113), 5 (126-138), 5-6(149-223), 7 (225-258), 8 (263-307), 10 (332-367).
Polymerase Chain Reaction:Article Title: Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion
Article Snippet: .. 2 , 0 , Tissue based , Knight Cancer Institute/Knight Diagnostic Laboratories , Sequenom MassARRAY system-multiplex PCR amplification of gene exons of interest; primer extension reaction using TYPLEX chemistry; readout of primer extension products by mass spectrometry. Multiplex panel of 496 assays that can detect up to 643 different mutations. , 10% , Not provided Only approximately 20% of potential mutations are covered in the TP53 gene.. .. 7 , 7 , Tissue based , MDACC 50-Gene Somatic Mutation Analysis Panel , PCR-based sequencing using a NGS-platform on genomic DNA to screen for mutations in the coding sequence of 50 genes , SNV 5%-10% , Hotspot technology PTEN 1 (1-25), 3 (55-70), 5 (99-135), 6 (165-184), 7 (212-215), 7 (231-267), 8 (282-300), 8 (312-342) TP53 2(1-20), 4 (68-113), 5 (126-138), 5-6(149-223), 7 (225-258), 8 (263-307), 10 (332-367).
Amplification:Article Title: Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion
Article Snippet: .. 2 , 0 , Tissue based , Knight Cancer Institute/Knight Diagnostic Laboratories , Sequenom MassARRAY system-multiplex PCR amplification of gene exons of interest; primer extension reaction using TYPLEX chemistry; readout of primer extension products by mass spectrometry. Multiplex panel of 496 assays that can detect up to 643 different mutations. , 10% , Not provided Only approximately 20% of potential mutations are covered in the TP53 gene.. .. 7 , 7 , Tissue based , MDACC 50-Gene Somatic Mutation Analysis Panel , PCR-based sequencing using a NGS-platform on genomic DNA to screen for mutations in the coding sequence of 50 genes , SNV 5%-10% , Hotspot technology PTEN 1 (1-25), 3 (55-70), 5 (99-135), 6 (165-184), 7 (212-215), 7 (231-267), 8 (282-300), 8 (312-342) TP53 2(1-20), 4 (68-113), 5 (126-138), 5-6(149-223), 7 (225-258), 8 (263-307), 10 (332-367).
Mass Spectrometry:Article Title: Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion
Article Snippet: .. 2 , 0 , Tissue based , Knight Cancer Institute/Knight Diagnostic Laboratories , Sequenom MassARRAY system-multiplex PCR amplification of gene exons of interest; primer extension reaction using TYPLEX chemistry; readout of primer extension products by mass spectrometry. Multiplex panel of 496 assays that can detect up to 643 different mutations. , 10% , Not provided Only approximately 20% of potential mutations are covered in the TP53 gene.. .. 7 , 7 , Tissue based , MDACC 50-Gene Somatic Mutation Analysis Panel , PCR-based sequencing using a NGS-platform on genomic DNA to screen for mutations in the coding sequence of 50 genes , SNV 5%-10% , Hotspot technology PTEN 1 (1-25), 3 (55-70), 5 (99-135), 6 (165-184), 7 (212-215), 7 (231-267), 8 (282-300), 8 (312-342) TP53 2(1-20), 4 (68-113), 5 (126-138), 5-6(149-223), 7 (225-258), 8 (263-307), 10 (332-367).
Multiplex Assay:Article Title: Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion
Article Snippet: .. 2 , 0 , Tissue based , Knight Cancer Institute/Knight Diagnostic Laboratories , Sequenom MassARRAY system-multiplex PCR amplification of gene exons of interest; primer extension reaction using TYPLEX chemistry; readout of primer extension products by mass spectrometry. Multiplex panel of 496 assays that can detect up to 643 different mutations. , 10% , Not provided Only approximately 20% of potential mutations are covered in the TP53 gene.. .. 7 , 7 , Tissue based , MDACC 50-Gene Somatic Mutation Analysis Panel , PCR-based sequencing using a NGS-platform on genomic DNA to screen for mutations in the coding sequence of 50 genes , SNV 5%-10% , Hotspot technology PTEN 1 (1-25), 3 (55-70), 5 (99-135), 6 (165-184), 7 (212-215), 7 (231-267), 8 (282-300), 8 (312-342) TP53 2(1-20), 4 (68-113), 5 (126-138), 5-6(149-223), 7 (225-258), 8 (263-307), 10 (332-367).
|
